May 15, 2023
|
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
|
|
April 27, 2023
|
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
|
|
March 13, 2023
|
Outlook Therapeutics® Confirms It Has No Exposure to Silicon Valley Bank
|
|
February 14, 2023
|
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
|
|
February 7, 2023
|
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference
|
|
January 19, 2023
|
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
|
|
January 9, 2023
|
Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
|
|
December 29, 2022
|
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
|
|
December 23, 2022
|
Outlook Therapeutics® Enters Definitive Agreement for $31.8 Million Unsecured Convertible Promissory Note
|
|
December 23, 2022
|
Outlook Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|